- COX-2 and NF-KB overexpression is common in pancreatic cancer but does not predict for COX-2 inhibitors activity in combination with gemcitabine and oxaliplatin. Cascinu, S., Scartozzi, M., Carbonari, G., Pierantoni, C., Verdecchia, L., Mariani, C., Squadroni, M., Antognoli, S., Silva, R.R., Giampieri, R., Berardi, R. Am. J. Clin. Oncol. (2007)